Previous Article | Next Article 
Molecular and Cellular Biology, March 2000, p. 1604-1615, Vol. 20, No. 5
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Putative Pore-Forming Domain of Bax Regulates
Mitochondrial Localization and Interaction with
Bcl-XL
Shahrzad
Nouraini,
Emmanuelle
Six,
Shigemi
Matsuyama,
Stainslaw
Krajewski, and
John
C.
Reed*
The Burnham Institute, La Jolla, California
92037
Received 13 September 1999/Returned for modification 21 October
1999/Accepted 29 November 1999
 |
ABSTRACT |
Bax is a proapoptotic member of the Bcl-2 family of proteins which
localizes to and uses mitochondria as its major site of action. Bax
normally resides in the cytoplasm and translocates to mitochondria in
response to apoptotic stimuli, and it promotes apoptosis in two ways:
(i) by disrupting mitochondrial membrane barrier function by formation
of ion-permeable pores in mitochondrial membranes and (ii) by binding
to antiapoptotic Bcl-2 family proteins via its BH3 domain and
inhibiting their functions. A hairpin pair of amphipathic
-helices
(
5-
6) in Bax has been predicted to participate in membrane
insertion and pore formation by Bax. We mutagenized several charged
residues in the
5-
6 domain of Bax, changing them to alanine.
These substitution mutants of Bax constitutively localized to
mitochondria and displayed a gain-of-function phenotype when expressed
in mammalian cells. Furthermore, substitution of 8 out of 10 charged
residues in the
5-
6 domain of Bax resulted in a loss of
cytotoxicity in yeast but a gain-of-function phenotype in mammalian
cells. The enhanced function of this Bax mutant was correlated with
increased binding to Bcl-XL, through a BH3-independent mechanism. These observations reveal new functions for the
5-
6 hairpin loop of Bax: (i) regulation of mitochondrial targeting and (ii)
modulation of binding to antiapoptotic Bcl-2 proteins.
 |
INTRODUCTION |
Members of the Bcl-2 family are
major regulators of apoptosis and include both pro- and antiapoptotic
proteins. Bax is a proapoptotic Bcl-2 family member which participates
in the induction of apoptosis in response to a variety of apoptotic
signals (4, 15, 27, 31). Furthermore, overexpression of Bax
induces apoptosis in many cells (31, 50). A number of
biochemical functions have been defined for Bax, some of which
correlate with its proapoptotic activity, including (i)
heterodimerization with the proapoptotic Bcl-2 proteins (9, 48,
49), (ii) homodimerization (8, 19, 51), (iii) release
of cytochrome c from mitochondria (14), and (iv)
disruption of the potential across the inner mitochondrial membrane
(32, 47). Recently, it has been shown that Bax functionally interacts with components of the mitochondrial inner membrane, the
adenine nucleotide transporter (ANT) (22), and the
mitochondrial F0F1 ATPase H+ pump
(24), as well as the outer membrane voltage-dependent anion
channel (VDAC) (40).
The three-dimensional structures of the Bcl-2 family members
Bcl-XL and Bid have been determined, revealing striking
resemblance to the pore-forming domains of certain bacterial toxins
(2, 25, 35). Moreover, Bcl-2 and Bax can be readily modeled
on the same X-ray crystallographic coordinates (36),
suggesting that they also possess similar protein folds. This
structural homology correlates with the ability of at least four
members of the Bcl-2 family, Bcl-XL, Bcl-2, Bid, and Bax,
to form ion-conducting pores in synthetic lipid membranes in vitro
(1, 26, 37-39). A hairpin pair of
-helices within the
pore-forming domains of bacterial toxins that share structural
similarity to Bcl-2 family proteins directly participates in membrane
insertion, leading to the generation of voltage-dependent
ion-conducting channels (3, 28). Similarly, deletion of the
corresponding
-helical hairpin in Bcl-2 and Bax (i.e.,
5 and
6) abrogates their ability to form ion-conducting pores in vitro
(23, 38), suggesting that this domain performs a similar
function in the Bcl-2 family.
The putative pore-forming
-helices in Bcl-2 family proteins are
amphipathic. When inserted into membranes, the polar residues of the
amphipathic
-helices presumably line the aqueous channels of pores,
and this would be expected to play an important role in mediating the
function of Bcl-2 family proteins in their capacity as pore-forming
proteins. Alternatively, since the
5-
6 domain is involved in
membrane insertion, the charged residues within this domain might
participate in or regulate interactions of Bax with other proteins
within mitochondrial membranes. We therefore generated a series of
alanine substitutions for charged residues within the
5 and
6
helices of Bax, evaluating the relevance of these polar residues to the
proapoptotic function of the Bax protein.
 |
MATERIALS AND METHODS |
Plasmids.
Bax mutants were constructed by the method of
two-step PCR mutagenesis (10), using a cDNA encoding the
open reading frame of mouse Bax (49). The final PCR products
were cloned into EcoRI and XhoI sites of the
pSKII plasmid, and the entire mouse Bax open reading frame was
sequenced. Subsequently, wild-type (WT) and mutant Bax cDNAs were
subcloned into the yeast expression plasmids pGilda (a gift of E. Golemis) and pEMBLGST (a gift of Elain Elion) as
EcoRI/XhoI and
SmaI/HindIII fragments, respectively. Bax is
expressed as a fusion protein with an N-terminal LexA DNA-binding domain and glutathione-S-transferase in the pGilda and
pEMBELGST plasmids, respectively. For mammalian expression, the
EcoRI/XhoI fragments of WT and mutant Bax cDNAs
were subcloned into the EcoRI/XhoI and
EcoRI/SalI sites of HA-pcDNA3 and pEGFP-C2,
respectively. Bax is expressed as a fusion protein C-terminal to three
contiguous HA tags and to green fluorescent protein (GFP) in HA-pcDNA3
and pEGFP-C2, respectively.
Yeast studies.
The yeast strains EGY48 and Brm-1 were used
for Bax-mediated cytotoxicity assays (24). Cells were
transformed by the lithium acetate method, using 1.0 µg of plasmid
DNA and 1.0 µg of sheared, denatured salmon sperm (carrier) DNA. To
test viability, transformant colonies were streaked on
histidine-deficient (pGilda-based plasmids) or uracil-deficient
(pEMBELGST-based plasmids) minimal medium containing either glucose or
galactose as a carbon source. The ability of the cells to grow in the
presence of Bax expression (on galactose-containing medium) was
monitored after incubation at 30°C for 4 to 5 days. For analysis of
protein expression, transformants were grown in the appropriate liquid
minimal medium containing glucose to an optical density at 600 nm of
0.4 to 0.5. The cells were washed in H2O three times before
incubation in minimal medium containing galactose for 12 h.
Cell culture, transfection, and mammalian-cell apoptosis
assays.
Cos-7 and 293T cells were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum, 1 mM
L-glutamine (final concentration), and antibiotics. The
transfection reagents Lipofectamine (Gibco BRL) and Superfect (Qiagen)
were used for transfection of Cos-7 and 293T cells, respectively. For
luciferase-based killing assays, 0.5 µg of either pEGFP-C2 or GFP
fusion plasmids, along with 0.1 µg of pGL3 control plasmid (Promega)
containing the firefly luciferase gene, was used to transfect 5 × 104 Cos-7 cells in 12-well tissue culture dishes. The
transfectants were washed with phosphate-buffered saline and harvested
using a luciferase assay system (Promega). Luciferase activity was
measured using a luminometer (MicroLumat LB96P; Wallac Inc.,
Gaithersburg, Md.). To test apoptotic activity in 293T cells, both
floating and adherent cells were pooled, fixed in 3.7%
paraformaldehyde, and subjected to staining with
4',6'-diamidino-2-phenylindole (DAPI) 6 to 18 h after transfection
with 2.0 µg of pcDNA3 or pEGFP-C2 plasmids encoding WT or mutant Bax.
For transfections with pcDNA3 constructs, 0.5 µg of
pEGFP-N2 was included to identify transfected cells. In
some transfections, zVAD-fmk (100 µM) was added 2 h after
transfection, and apoptotic and cytotoxic activity was assessed by DAPI
staining and propidium iodide (PI) dye exclusion, respectively, 48 h posttransfection. To test suppression of Bax activity by Bcl-XL, 0.5 µg of either WT or mutant GFP fusion plasmids
was cotransfected with 1.5 µg of either pcDNA3-Bcl-XL or
pcDNA3 into 293T cells. Cytotoxic and apoptotic assays were performed
as described above at 48 h posttransfection.
Confocal microscopy.
Cos-7 cells (104) in
eight-chambered glass slides (LabTek) were transfected with 0.25 µg
of either pEGFP-C2 or GFP-Bax (WT or mutant) fusion constructs using
0.75 µl of Lipofectamine. The cells were incubated with or without
Staurosporine (STS) (1 µM final concentration) for 4 h, after
which they were fixed with 2% paraformaldehyde. To test the
localization of Bax in 293T cells, 6 × 105 cells were
transfected with 2.0 µg of the above-mentioned plasmids and the cells
were harvested 6 h posttransfection, fixed with 2%
paraformaldehyde, and mounted on a glass slide. The localization of GFP
and GFP fusion proteins was monitored by confocal microscopy using a
Bio-Rad laser confocal microscope (MRC-1024).
Immunoblot and immunoprecipitation studies.
For immunoblot
assays involving yeast, extracts were prepared by breaking the cells
using glass beads in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris
[pH 7.4], 1% NP-40, and protease inhibitors). Aliquots containing 10 µg of total protein were separated in sodium dodecyl sulfate
(SDS)-10% polyacrylamide gels, transferred to Immobilon P nylon
membranes, and incubated with a polyclonal rabbit anti-LexA antiserum
(a gift of E. Golemis). Antigen was detected by incubation of the blots
with horseradish peroxidase secondary antibodies followed by the
Enhanced ChemiLuminescence detection kit (Amersham). For mammalian
expression studies, cells were lysed in radioimmunoprecipitation assay
buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.5%
deoxycholate, 0.1% SDS, 5 mM EDTA, and protease inhibitors). Aliquots
of extracts containing 5 to 30 µg of total protein were analyzed by
SDS-polyacrylamide gel electrophoresis immunoblotting as described
above. Antigen detection was accomplished using either a polyclonal
rabbit anti-mouse Bax (16) or a monoclonal antibody to GFP (Clonetech).
For immunoprecipitation experiments, Cos-7 cells (7.5 × 105/10-mm-diameter dish) were transfected with 5.0 µg of
FLAG-Bcl-XL in pcDNA3 and 5.0 µg of either pEGFP-C2 or
GFP fusion Bax plasmids, using 30 µl of Lipofectamine. zVAD-fmk was
added to cultures 2 h posttransfection, and the cells were
incubated for a further 20 h. Cell extracts were prepared using an
isotonic lysis buffer (142.5 mM KCl, 1 mM EGTA, 5 mM MgCl2,
10 mM HEPES [pH 7.4], 0.2% NP-40, and protease inhibitors).
Following preclearing of extracts with agarose-GST, Bcl-XL
complexes were immunoprecipitated using an anti-FLAG M2-agarose
affinity gel (Sigma). The immune complexes were denatured by boiling
them in the presence of Laemmli sample buffer, and aliquots from each
sample were loaded into SDS-12% polyacrylamide gels. The presence of
Bcl-XL and GFP-Bax (WT or mutant) complexes was monitored
by immunoblotting using a polyclonal anti-human Bcl-XL
(17) and a monoclonal anti-GFP antibody, respectively.
Subcellular fractionation.
Cos-7 cells (3 × 106/20-mm-diameter plate) were transfected with 18 µg of
HA-pcDNA3 Bax (WT or mutant) along with 2 µg of pEGFP-C2 plasmid,
using 60 µl of Lipofectamine. zVAD-fmk (50 µM) was added to the
cell cultures 2 h posttransfection, and the cells were incubated
for a further 20 h. Then the cells were incubated in the presence
or absence of STS (1 µM) for 4 h. Cell extracts were prepared in
a hypotonic buffer (5 mM Tris-HCl [pH 7.4], 5 mM KCl, 1.5 mM
MgCl2, and protease inhibitors), and fractionated as
previously described (43). The heavy-membrane (HM) and
light-membrane (LM) fractions were boiled in 100 µl of Laemmli
buffer. The soluble fraction was mixed with one-third volume of a
4×-concentrated Laemmli solution and boiled. Aliquots of fractions
normalized for cell equivalents were separated on SDS-12%
polyacrylamide gels and transferred to Immobilon nylon membranes.
Antigen detection was performed using a rat monoclonal
antihemagglutinin (anti-HA) high-affinity antibody (Boehringer
Mannheim) and a rabbit polyclonal anti-human Bcl-2 antiserum
(27). For alkali extractions using HM mitochondrion-enriched
fractions, cell extracts were prepared in buffer A (20 mM HEPES [pH
7.4], 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
dithiothreitol, and protease inhibitors). After a low-speed
centrifugation to pellet whole cells and nuclei, the cell extract was
divided into two portions, each of which was centrifuged to obtain an
HM fraction. One HM fraction was resuspended in a mitochondrial
resuspension buffer (120 mM mannitol, 70 mM sucrose, 1 mM EDTA, 1 mM
EGTA, and 10 mM HEPES [pH 7.5]). The other HM preparation was
resuspended in the same volume of freshly prepared 0.1 M
Na2CO3 (pH 11.5). Both HM fractions were
incubated on ice for 30 min, followed by centrifugation for 10 min at
170,000 × g in a Beckman airfuge. Mitochondrial
pellets and supernatants were boiled in Laemmli sample solution,
normalized for cell equivalents, and separated in SDS-12%
polyacrylamide gels. Protein was blotted onto Immobilon-P nylon
membranes and probed with a rat monoclonal anti-HA high-affinity
antibody (Boehringer Mannheim), a mouse monoclonal antibody to human
mitochondrial Hsp60 (Santa Cruz), and a mouse monoclonal antibody
(Molecular Probes) recognizing subunit II of human cytochrome
c oxidase (COX-II).
 |
RESULTS |
Cytotoxicity of Bax alanine substitution mutants in yeast.
The
putative pore-forming
5-
6 region of Bax is predicted to comprise
a hairpin-pair of amphipathic
-helices which contains 10 charged
residues (Fig. 1). We systematically
replaced these charged residues with alanine to investigate their
significance for the killing activity of Bax. Bax confers a lethal
phenotype when ectopically expressed in the lower eukaryote
Saccharomyces cerevisiae, with characteristics similar to
that imposed by Bax on mammalian cells, including induction of
cytochrome c release from mitochondria and disruption of
mitochondrial membrane potential in a manner that is suppressible by
Bcl-2, Bcl-XL, and Mcl-1 (13, 21, 34, 50). It is
highly likely that the ability of Bax to kill yeast is related to its
intrinsic activity as a pore-forming protein for two reasons: (i) yeast
lacks Bcl-2 family proteins and (ii) deletion of the
5-
6 region
of Bax abrogates its lethal effect in yeast (23). As such,
yeast provides a convenient readout system for understanding
structure-function relations within Bax protein which are relevant to
its pore-like activity. Thus, we initially analyzed the cytotoxic
activity of the Bax mutants in the yeast S. cerevisiae
strain EGY48. For these experiments, WT and mutant versions of Bax were
expressed in yeast under the control of the GAL1 promoter,
which permits repression and induction of Bax protein expression, by
plating cells on media containing glucose or galactose, respectively.
As shown in Fig. 2A, the cytotoxic activity of Bax is not compromised upon alanine substitution for up to
7 of 10 charged residues within
5-
6; however, replacement of an
additional charged residue (R109), leaving E131 and R147 as the only
charged residues, completely abrogated the killing activity of Bax in
yeast. Single substitution of tryptophan for the R109 residue did not
lead to loss of Bax activity (not shown), suggesting a requirement for
multiple substitutions in the putative pore-forming domain for
inactivation of the cytotoxic function of Bax in yeast. Measurement of
protein expression by immunoblotting (Fig. 2B) showed that the loss of
activity of the multiply substituted Bax mutant was not due to
instability of the mutant protein.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 1.
Diagram of mutations generated in Bax. (Top) Ribbon
diagrams of the 5- 6 helical hairpin of Bax. The hypothetical
three-dimensional structure of Bax was modeled, based on the
coordinates available for Bcl-XL, using the Quanta software
package (Molecular Simulations, San Diego, Calif.). The charged
residues lining the helical hairpin (residues N106 to Q153) are shown
as ball-and-stick representations for WT Bax (A). To illustrate the
mutagenic alterations (B to F), the ball-and-stick representations for
the residues replaced by alanine are omitted. (Bottom) Amino acid
sequence of the 5- 6 regions of WT and mutant Bax proteins.
Although the 5- 6 region contains a total of 10 charged residues,
we have not considered R147, since it is present in the opposite side
of all other charged residues. Accordingly, the ball-and-stick
representation of this residue is not depicted in the ribbon diagrams
above. The letters on the left correspond to the panels above. The
dashes represent residues identical to those in sequence A.
|
|

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 2.
Cytotoxic activity and expression of Bax mutants in
yeast. (A) Yeast strain EGY48 was transformed with 1.0 µg of either
the empty yeast expression vector pGilda (Cont.) or pGilda containing
WT Bax or the various Bax alanine substitution mutants (the letters
correspond to those in Fig. 1). Individual transformant colonies were
streaked on histidine-deficient (His ) medium containing
glucose (Bax expression repressed) or His -galactose (Bax
expression induced) semisolid medium and incubated at 30°C for 4 days. (B) Immunoblot results are shown for lysates (10 µg) of yeast
cells grown in His -galactose medium for 12 h. The
blot was incubated with anti-LexA antiserum, followed by enhanced
chemiluminescence-based detection.
|
|
Neutralization of charged residues in the
5-
6 region of Bax
enhances apoptotic and cytotoxic activities.
To further evaluate
the characteristics of Bax mutants, we first concentrated on Bax
mutants B and C, which remain active in yeast and which, among the
mutants tested, have the fewest substitutions in the pore-forming
domain. Although neutralization of charged residues in the
5-
6
domain did not inactivate the cytotoxicity of Bax in yeast, we
considered the possibility that some of these residues in the
5-
6
helix might be required for apoptosis in mammalian cells. For this
reason, the apoptotic activity of Bax mutants B (K119A and K123A) and C
(K119A, K123A, D142A, R145A, and E146A) was compared with WT Bax in
transient-transfection assays in 293T and Cos-7 cells. The Bax B and C
mutants induced higher percentages of apoptosis in 293T cells than did
WT Bax (Fig. 3A). Similarly, the B and C
mutants of Bax were more potent than WT Bax at inducing cell death in
Cos-7 cells (Fig. 3B) when tested in a cytotoxicity assay that uses
luciferase activity as an endpoint for determining relative numbers of
surviving cells (45). Comparison of the steady-state levels
of WT and mutant Bax proteins by immunoblot analysis of lysates
prepared from 293T and Cos-7 transfectants revealed that the B and C
mutant Bax proteins were generally present at slightly lower levels
than WT Bax, excluding excessive production of mutants as an
explanation for their apparent gain-of-function phenotypes.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
Bax mutants B and C display a gain-of-function phenotype
in mammalian and yeast cells. (A) 293T cells were transfected with
empty HA-pcDNA3 vector (bar 1) or pcDNA3 encoding HA-tagged WT Bax (bar
2) or mutant Bax-B (bar 3) or Bax-C (bar 4) protein. The percentage of
apoptotic cells (+ standard deviation [SD]) was determined by DAPI
staining at 8 h posttransfection. The inset shows an immunoblot
analysis of the cells transfected with HA-pCDNA3 (lane 1)
or plasmids encoding WT Bax (lane 2) and mutant Bax-B (lane 3) and
Bax-C (lane 4), detected with a polyclonal anti-mouse Bax antiserum.
(B) Cos-7 cells were transfected with 0.1 µg of the
luciferase-encoding plasmid pGL3 control, along with either empty
pEGFP-C2 (bar 1), pEGFP-C2-Bax WT (bar 2), pEGFP-C2-Bax mutant B (bar
3), or pEGFP-C2-Bax mutant C (bar 4). The amount of luciferase
activity measured for WT and mutant Bax was normalized to that obtained
for pEGFP-C2 alone, taking the latter as 100% activity. The results
were then subtracted from 100% and plotted as percent inhibition. The
data shown represent the averages of three different experiments, each
performed in duplicate (mean + SD). The inset shows expression of
GFP-WT Bax (lane 2) or GFP-mutant Bax (lanes 3 and 4) proteins detected
with a monoclonal antibody to GFP. Lane 1 contains extract from cells
transfected with empty vector. (C) The Bax-resistant yeast strain Brm-1
was transformed with 1.0 µg of empty pEMBELGST vector, or pEMBELGST
encoding WT Bax or Bax mutants B and C. Transformants were selected on
Ura -glucose+ medium, and individual colonies
were grown on Ura -glucose+ medium (Bax
expression repressed) or Ura -galactose+
medium (Bax expression induced) for 4 days at 4°C.
|
|
To investigate whether the increase in apoptotic activity of Bax
mutants is also manifested in yeast, we tested the killing
activity of
the B and C Bax mutants in the yeast strain Brm-1
(for Bax-resistant
mutant 1), which, as we have shown previously,
is resistant to the
cytotoxic activity of WT Bax (
24). In contrast
to WT Bax,
which was unable to kill the Brm-1 yeast strain, the
gain-of-function
Bax mutants were cytotoxic, preventing the growth
of Brm-1 cells on
galactose-containing medium, which induces production
of these proteins
(Fig.
3C). Immunoblot analysis suggested that
the enhanced activity of
the B and C Bax mutants was not due to
higher levels of protein
production than WT Bax (not shown). We
concluded, therefore, that the B
and C mutants of Bax display
a gain-of-function phenotype in both
mammalian cells and
yeast.
Cytotoxic activity of gain-of-function mutants of Bax is nullified
by Bcl-XL but not by the caspase inhibitor zVAD-fmk.
It has been shown that the cytotoxic activity of Bax arises from two
separable components which are caspase dependent and independent
(14, 47, 50), with the latter ascribed to the intrinsic
function of Bax as a pore-forming protein (reviewed in references
7 and 33). The intrinsic
caspase-independent activity of Bax can be monitored by culturing
Bax-overexpressing cells in the presence of the broad-spectrum caspase
inhibitor zVAD-fmk. Accordingly, 293T cells were transiently
transfected with plasmids encoding WT or mutant Bax proteins and then
cultured in the presence or absence of zVAD-fmk. The percentages of
apoptotic and dead cells were measured after 48 h by DAPI staining
and by PI dye exclusion assays, respectively (43, 50). As
shown in Fig. 4A, when tested in the
absence of zVAD-fmk, WT Bax and the Bax B and C mutants induced both
apoptosis and cell death of transiently transfected 293T cells, with
the B and C mutants displaying enhanced cytotoxic activity relative to
that of WT Bax. In contrast, addition of zVAD-fmk almost completely
prevented Bax-induced apoptosis but did not block cell death induction.
Moreover, the Bax B and C mutants continued to exhibit enhanced
cytotoxic activity relative to WT Bax, even in the presence of zVAD-fmk
(Fig. 4). In contrast to zVAD-fmk, which only suppressed Bax-induced
apoptosis but not cell death, Bcl-XL suppressed both
apoptosis (nuclear fragmentation as revealed by DAPI staining) and cell
death (PI dye uptake) induced by WT and mutant Bax proteins (Fig. 4B).
These data argue that the enhanced cytotoxicity of the B and C mutants
does not arise through nonspecific mechanisms, since it is suppressible
by Bcl-XL.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
Inhibition of apoptotic and cytotoxic activity of WT and
mutant Bax by zVAD-fmk and Bcl-XL. (A) zVAD-fmk inhibits
the apoptotic but not the cytotoxic activity of WT and mutant Bax.
Empty HA-pcDNA3 (Cont) or pcDNA3 encoding HA-WT Bax, Bax-B, or Bax-C (2 µg each) was transfected into 293T cells, followed by culturing in
the presence (+) or absence ( ) of 100 µM zVAD-fmk. The percentages
of apoptotic cells and dead cells were measured by DAPI staining of the
nuclei and cellular uptake of PI, respectively, 2 days posttransfection
(mean + standard deviation [SD]; n = 3). (B)
Bcl-XL inhibits both the apoptotic and cytotoxic activities
of WT and mutant Bax. Control HA-pcDNA3 plasmid (Cont) or HA-pcDNA3
plasmids encoding WT Bax or HA-Bax mutants (0.5 µg), were transfected
into 293T cells, with or without 1.5 µg of pcDNA3-Bcl-XL.
The cells were scored for apoptotic nuclei and cytotoxic cell death
(means + SD) by DAPI staining of nuclei and uptake of PI,
respectively, 2 days after transfection.
|
|
Gain-of-function Bax mutants induce apoptosis with accelerated
kinetics.
To investigate whether the enhanced apoptotic activity
of Bax mutants was due to a higher rate of apoptosis induction versus an absolute increase in potency, the time course of apoptosis induction
was examined in cultures of 293T cells following transfection with
plasmids encoding WT Bax or the B and C mutants of Bax. The GFP-encoding pEGFP-N2 plasmid was included in all the
transfections to monitor transfection efficiency. Although WT Bax
induced a lower percentage of transfected cells to undergo apoptosis
than did the gain-of-function mutants at 6 h posttransfection,
given sufficient time, the apoptotic activity exhibited by WT Bax
approached that of the B and C mutants (Fig.
5). Immunoblotting experiments indicated
that the faster kinetics of apoptosis induction exhibited by the B and
C mutants was not attributable to accelerated production of these
proteins in transfected cells compared to WT Bax (Fig. 5, inset).
Indeed, WT Bax protein levels were consistently higher than those of
Bax-B or Bax-C proteins. This observation suggests that the
gain-of-function Bax mutants bypass a rate-limiting step required for
Bax protein activation or function.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 5.
Gain-of-function Bax mutants kill 293T cells with
accelerated kinetics. Plasmid HA-pcDNA3 (Vector) or HA-pcDNA3 encoding
WT-Bax (Bax) or mutants Bax-B (B) and Bax-C (C) (2.0 µg each) was
transfected into 293T cells. The percentages of apoptotic nuclei were
scored 6, 12, and 18 h after transfection (mean ± standard
deviation; n = 3). The inset is an immunoblot showing
the expression of WT and mutant Bax at 6 and 8 h after
transfection, using a polyclonal anti-mouse Bax antiserum.
|
|
Bax mutants constitutively localize to mitochondria.
Previously, it has been shown that Bax protein resides in the cytosol
of some types of cells, undergoing translocation to mitochondrial
membranes upon receiving an apoptotic stimulus (11, 12, 46).
Since the only early rate-limiting step thus far identified in the Bax
pathway for apoptosis is the localization of Bax to mitochondria, we
used fluorescence microscopy to monitor the subcellular localization of
GFP-tagged WT and mutant Bax proteins. These experiments were performed
using Cos-7 cells, in which it has been reported that STS induces the
translocation of Bax to mitochondria (11, 12, 46). As shown
in Fig. 6A, Bax displayed a uniform
distribution in unstimulated Cos-7 cells but localized to cytosolic
organellar structures upon treatment with STS. In contrast, the B and C
mutants of Bax exhibited a punctate cellular distribution in both the
presence and absence of STS (Fig. 6A [only mutant B is shown]).
Two-color analysis using a mitochondrion-specific dye (Mitotracker C)
confirmed colocalization of Bax to mitochondria following exposure to
STS (not shown). We conclude, therefore, that the alanine substitutions
in the hyperactive mutants B and C modify the subcellular distribution
of these proteins, allowing constitutive mitochondrial localization.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 6.
Bax gain-of-function mutants constitutively localize to
cellular membranes. (A) Cos-7 cells were transfected with either
pEGFP-C2 or pEGFP-C2 encoding WT Bax or mutant Bax-B. After 20 h
of transfection, the cells were incubated with or without STS for
4 h. The cells were fixed, and the localization of GFP and GFP
fusion proteins was determined using confocal microscopy. (B)
Localization of GFP and various GFP-Bax fusion proteins at 6 h
posttransfection in 293T cells. Healthy (non-Apop) and apoptotic (Apop)
cells are shown.
|
|
Similar observations were made using 293T cells. In 293T cells, WT Bax
constitutively targets mitochondria when overexpressed
by transient
transfection without the necessity for additional
apoptotic stimuli
(
50). By monitoring GFP-Bax localization in
293T cells at
various times after transfection, we observed that
WT GFP-Bax was
diffusely distributed throughout most cells at
6 h
posttransfection (Fig.
6B, left), localizing to mitochondria
only in
apoptotic cells (Fig.
6B, right). In contrast, the GFP-tagged
Bax B and
C mutants exhibited a punctate distribution indicative
of mitochondrial
localization in essentially all cells examined
at 6 h
posttransfection (Fig.
6B). Cotransfection of Bcl-X
L did
not alter the punctate distribution of Bax mutants in 293T or
Cos-7
cells (not shown) but did prevent Bax-induced cell
death.
To confirm that the punctate distribution of Bax mutants represents
constitutive mitochondrial localization, we performed
subcellular-fractionation experiments using cell lysates from
Cos-7
cells which had been transiently transfected with plasmids
encoding
HA-tagged WT Bax or Bax mutant B. The cells were cultured
in the
presence or absence of STS prior to preparation of soluble
(cytosolic),
LM, and HM fractions. As shown in Fig.
7A, WT Bax
was located predominantly in
the soluble fractions of unstimulated
Cos-7 cells, with a negligible
association with membrane fractions
in the absence of STS. In contrast,
in extracts prepared from
STS-treated cells, WT Bax was clearly
detected in both the LM
and mitochondrion-enriched HM fractions.
Although some of the
mutant B and C Bax protein was found in the
soluble fraction,
a considerable proportion of the Bax-B (Fig.
7A) and
Bax-C (not
shown) localized to intracellular membranes, including
mitochondria,
in the absence of STS, unlike WT Bax. These observations
thus
confirm the results obtained by confocal microscopy using
GFP-tagged
proteins. Furthermore, the HM-associated Bax-B and Bax-C
proteins
were mostly membrane inserted, based on their resistance to
extraction
from membranes by alkali (Fig.
7B and not shown).
Examination
of soluble (Hsp60) and integral (COX-II) membrane
mitochondrial
proteins as controls verified successful use of the
alkali extraction
procedure for assessing the status of WT and mutant
Bax proteins
(Fig.
7B). We conclude, therefore, that a large fraction
of the
Bax-B and Bax-C gain-of-function mutant proteins constitutively
target and insert in membranes prior to any evidence of apoptosis
or
stimulation with exogenous apoptosis-inducing agents.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 7.
Analysis of Bax mutants by subcellular fractionation and
alkali extraction. Cos-7 cells were transfected with 18 µg of pcDNA3
encoding HA-Bax or HA-Bax-B, followed by incubation for 20 h.
Then the transfectants were incubated for 4 h with or without STS.
(A) Cell extracts were prepared and fractionated into soluble (S),
light-membrane (L), and HM (H) fractions. Aliquots from each fraction
normalized to cell equivalents were monitored for the presence of
transfected HA-Bax (WT or mutant) and for endogenous Bcl-2 protein by
immunoblot analysis using rat monoclonal anti-HA and polyclonal
anti-human Bcl-2 antibodies, respectively. (B) Mitochondrion-enriched
HM pellets were resuspended in either Na2CO3
(pH 11.5) or mitochondrial isolation buffer (pH 7.4). After 30 min of
incubation on ice, the mitochondria were pelleted and resuspended in
Laemmli sample buffer. Equal proportions of the mitochondrial
supernatants (S) and pellets (P) were analyzed by immunoblotting and
probing for the presence of HA-Bax (WT or mutant), COX-II (inner
membrane), or Hsp60 (matrix or soluble). +, present; , absent.
|
|
As shown in Fig.
6, mutant Bax-B has a punctate localization throughout
the cytoplasm in healthy cells, consistent with the
presence of both
soluble and membrane-bound Bax-B protein detected
in subcellular
fractionation experiments (Fig.
7A). However, in
apoptotic cells,
GFP-Bax-B becomes solely concentrated on mitochondria
such that the
distributions of mutant and WT Bax become indistinguishable
under these
conditions (Fig.
6). It has been suggested that in
response to
apoptotic stimuli, a fraction of soluble Bax localizes
to mitochondria
and the remaining soluble Bax is removed by proteolysis
(
5).
Thus, the difference in the cellular distributions of
GFP-Bax-B
protein in healthy and apoptotic cells might be due
to proteolysis of
the fraction of Bax that remains soluble after
receipt of an apoptotic
signal. Alternatively, the fraction of
soluble Bax-B might undergo a
conformational change and translocate
to mitochondria in apoptotic
cells. Nevertheless, the combined
data presented in Fig.
6 and
7
indicate that, unlike WT Bax, a
large fraction of mutant Bax-B protein
constitutively localizes
to mitochondria, correlating with a
gain-of-function
phenotype.
The mutant Bax-F reveals a dual function for the
5-
6
domain.
Having evaluated the effects of the Bax mutants (B and C)
which contained fewer alanine replacements and which retained cytotoxic activity in yeast, we next turned our attention to the Bax-F mutant, which displayed a loss-of-function phenotype in yeast (Fig. 2) and in
which 8 out of 10 charged residues in the
5-
6 domain of Bax had
been neutralized. In contrast to the results obtained in yeast, when
expressed by transient transfection in 293T and Cos-7 cells, a
GFP-tagged Bax-F mutant displayed a gain-of-function phenotype (Fig.
8) and constitutive localization to
cellular membranes (not shown). Similar to Bax mutants B and C, Bax-F
showed enhanced cytotoxic activity which was suppressed by
Bcl-XL (not shown) but not by zVAD-fmk (Fig. 8C).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 8.
Apoptotic and cytotoxic activity of Mutant Bax F in
mammalian cells. (A and B) Mutant Bax F displays a gain-of-function
phenotype in mammalian cells. Plasmids encoding GFP-tagged WT, mutant
F, mutant F+BH3, or mutant BH3 (D68A) Bax were transfected into 293T
(A) and Cos-7 (B) cells and assayed for apoptosis 5 (A) and 16 (B) h
posttransfection, respectively. Protein expression was tested in 293T
cells (A, bottom) using either 5 (lanes 1, 3, 5, and 7) or 10 (lanes 2, 4, 6, and 8) µg of protein from extracts of cells transfected with
plasmids encoding GFP-Bax (lanes 1 and 2), GFP-F (lanes 3 and 4),
GFP-(F+BH3) (lanes 5 and 6), or GFP-BH3 (lanes 7 and 8). For
measurement of protein expression in Cos-7 cells (B, bottom), 10 µg
of proteins from cells expressing GFP-Bax (lane 1), GFP-F (lane 2),
GFP-(F+BH3) (lane 3), or GFP-BH3 (lane 4) was analyzed. Antigen
detection for both 293T and Cos-7 extracts was accomplished using
monoclonal anti-GFP antibody. (C) zVAD-fmk inhibits the apoptotic, but
not the cytotoxic, activity of mutant F. Plasmid DNA was transfected
into 293T cells, and zVAD-fmk (100 µM) was added to the cell culture
medium 2 h posttransfection. Apoptosis and cytotoxicity were
measured by DAPI staining and PI dye exclusion assays, respectively,
48 h posttransfection. The error bars indicate standard deviation.
+, present; , absent.
|
|
Since the cytotoxic activity of Bax in yeast has been attributed to the
intrinsic pore-forming activity of Bax, we considered
the possibility
that the gain-of-function phenotype of Bax mutant
F in mammalian cells
relates to its ability to bind antiapoptotic
Bcl-2 family proteins
which are not present in yeast. To test
this hypothesis, we made a
combination mutant (F+BH3) in which
the F mutation was combined with an
alanine substitution for the
D68 residue in the BH3 domain. Previously,
it has been shown that
the BH3 domain is the minimal region of Bax
required for binding
to antiapoptotic Bcl-2 proteins and that a D68A
substitution greatly
inhibits this interaction (
44,
49,
51).
The apoptotic activity
of the GFP-tagged F+BH3 mutant was compared to
that of GFP-tagged
WT Bax, Bax-F, and Bax-D68A mutants by transient
transfection
in 293T and Cos-7
cells.
As shown in Fig.
8, the F+BH3 combination mutant exhibited reduced
apoptotic and cytotoxic activity compared to the F mutant
in 293T and
Cos-7 cells. This reduced activity was not attributable
to a change in
cellular distribution (not shown) or to impaired
production of
Bax-(F+BH3) protein, as determined by immunoblot
analysis (Fig.
8).
However, in both 293T and Cos-7 cells, the
F+BH3 mutant retained some
killing activity, despite disruption
of its BH3 domain and
neutralization of most charged residues
in its

5-

6
region.
In an effort to probe the mechanism responsible for the enhanced
function of the Bax-F mutant and the residual activity of
the
Bax-(F+BH3) mutant, we performed coimmunoprecipitation experiments
exploring the association of these mutants with Bcl-X
L. For
these
experiments, Cos-7 cells were transiently transfected with
plasmids
encoding GFP, GFP-Bax, GFP-Bax-F, GFP-Bax-BH3, or
GFP-Bax-(F+BH3),
along with FLAG-tagged Bcl-X
L.
Immunoprecipitations were then
performed with anti-FLAG antibody, and
the resulting immune complexes
were analyzed for associated Bax protein
by SDS-polyacrylamide
gel electrophoresis immunoblotting. As shown in
Fig.
9, the BH3
domain D68A mutation
greatly reduced the interaction of Bax with
Bcl-X
L (compare
lanes 2 and 3), as previously reported (
51).
However, when
examined in combination with the F mutations, the
BH3 domain D68A
mutation only partially reduced interaction with
Bcl-X
L,
compared to WT Bax (Fig.
9, lane 5). Moreover, the Bax
mutant F
displayed enhanced interaction with Bcl-X
L compared to
that
of WT Bax (Fig.
9, compare lanes 2 and 4). These observations
correlate
with the inability of the BH3 domain D68A mutation to
completely
abolish the apoptotic activity of Bax when combined
with the

5-

6
mutant F and provide an explanation for the gain-of-function
phenotype
of mutant F, despite its lack of cytotoxic activity
in yeast.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 9.
The gain-of-function phenotype of Bax mutant F
correlates with increased binding to Bcl-XL. Cos-7 cells
were transfected with pcDNA3 encoding FLAG-tagged Bcl-XL,
along with plasmids encoding GFP (lane 1) or GFP fusions of WT Bax
(lane 2) or Bax mutant F (lane 4), F+BH3 (lane 5), or BH3 (lane 3).
Cell extracts were subjected to immunoprecipitation with a monoclonal
antibody to the FLAG epitope. The immune complexes and 1/40 of the
extract used for coimmunoprecipitations were analyzed by
immunoblotting, using a monoclonal antibody to GFP and a polyclonal
anti-human Bcl-XL antiserum. IP, immunoprecipitate.
|
|
 |
DISCUSSION |
The
5-
6 helical hairpin of Bax has been implicated in the
formation of ion-conducting channels in cellular membranes, by analogy
to prior work performed with structurally similar bacterial toxins
(3, 23). The analogous
-helices of colicins have been
shown to insert into membranes, based on electron paramagnetic resonance and fluorescence probe studies (3). Accordingly, the presence of charged residues in the
5-
6 region of Bax imposes certain restrictions on the membrane-inserted state of this protein. One of these is that energetic barriers exist to attaining the membrane-inserted state, since polar residues must be driven into an
apolar environment. Second, once inserted into the membrane, the
charged residues, residing on one face of each of the amphipathic
-helices in the
5-
6 domain, must be somehow shielded from the lipid bilayer. The most straightforward mechanism for accomplishing this shielding is by directing the polar face of the membrane-inserted
-helices towards the aqueous lumen of a channel and having two or
more Bax molecules collaborate by contributing pairs of
-helices that can form a ring around this lumen (reviewed in references 28 and 36). Presumably, this
highly charged aqueous lumen would participate in the channel formation
and cytotoxicity of Bax by allowing passage of ions through the
membrane. We predicted, therefore, that neutralizing charged residues
in the
5-
6 region of Bax should make it easier for the protein to
attain a membrane-inserted state but also might impair its ability to
form ion-permeable cytotoxic channels. The systematic alanine
substitutions reported here support these concepts but also reveal
previously unidentified functions for the
5-
6 helical hairpin of Bax.
5-
6 helical hairpin of Bax as regulator of membrane
insertion.
We have shown that neutralization of as little as two
charges in the
5 helix of Bax allows the protein to localize to
cellular membranes, including mitochondria. Mitochondria represent a
major site of action of Bcl-2 family proteins. Although the
antiapoptotic proteins Bcl-2 and Bcl-XL are predominantly
localized to mitochondria and other cellular membranes (46),
the proapoptotic protein Bax is normally cytosolic and migrates to the
mitochondria in response to undefined apoptotic signals (11, 20,
46). Previous mutational analysis, aimed at determining the
regulatory event(s) leading to mitochondrial localization of Bax, have
concentrated on the C-terminal hydrophobic domain (TM domain) of this
protein (6, 30). The results of these studies suggest that
an interaction between the TM domain and the N-terminal first 20 amino
acids of Bax prevents Bax from localizing to mitochondria and that a conformational change disrupts this interaction, leading to
mitochondrial targeting and membrane insertion (6, 30). The
work presented here implicates the charged residues in the
5 helix
of Bax as additional determinants of mitochondrial localization. Since
the K119A and K123A substitutions in the
5 helix of Bax resulted in
mitochondrial localization of a large fraction of mutant B and led to
enhanced apoptotic activity, we suggest that either or both of the
positively charged residues K119 and K123 are required for maintaining
Bax in an aqueous-soluble state. Similar mutational analysis of the
membrane insertion
-helical hairpin of diphtheria toxin has shown
that substitution of positively charged residues for acidic residues in
the loop connecting the two
-helices in this domain (
-helices 8 and 9) blocks membrane insertion (41). This suggests that
the presence of positively charged residues is inhibitory for
membrane insertion and is consistent with the previously documented
energetic unfavorability of inserting positively charged residues into
membranes (18). Interestingly, previous studies have shown
that enforced dimerization of Bax leads to mitochondrial localization
and apoptosis in the absence of external apoptotic stimuli (8,
44). Conceivably, therefore, Bax homodimerization might
additionally promote membrane insertion by masking positive charges
within the
5-
6 domain.
The
5-
6 helical hairpin as regulator of intrinsic cytotoxic
activity of Bax.
The cytotoxic activity of Bax in yeast has been
attributed to the intrinsic pore-forming capacity of Bax, based on the
observation that deletion of the
5-
6 region nullifies the ability
of Bax to induce cell death in yeast (23) and due to the
absence of Bcl-2 homologues in yeast (reviewed in references
7 and 33). Furthermore, it has
recently been shown that Bax functionally interacts with other
evolutionarily conserved channel proteins resident in mitochondrial
membranes, such as VDAC, ANT, and the F0F1
ATPase proton pump, in both yeast and mammalian cells (22, 24, 29,
42). Bax mutants B and C, which largely localize to mitochondria,
display gain-of-function phenotypes in both mammalian cells and the
Bax-resistant mutant yeast strain Brm-1. Thus, we hypothesize that
enhanced membrane insertion facilitates channel formation or
interaction with the above-mentioned mitochondrial channel proteins.
Since mutant F constitutively localizes to mitochondria but lacks
lethal activity in yeast, we predict that this protein is defective in
channel activity and/or interaction with other mitochondrial channel
proteins. Despite substantial effort, we have been unable to produce
any of the Bax mutants as recombinant proteins suitable for direct
measurement of channel activity, precluding the determination of the
precise biochemical activities that are responsible for the
gain-of-function phenotype of mutants B and C and the loss-of-function
phenotype of mutant F in yeast.
The
5-
6 region of Bax as a regulator of interactions with
Bcl-XL.
Previous studies have suggested that Bax has
two mechanisms for killing mammalian cells: one linked to its intrinsic
function as a channel-forming or membrane-inserted protein mediated by its
5-
6 region and the other attributable to its ability to dimerize with proapoptotic Bcl-2 family proteins through its BH3 domain, nullifying their cell survival functions (44, 47, 49). Thus, ablating either of these mechanisms individually through mutagenesis of the Bax protein is insufficient to abolish its
proapoptotic function in mammalian cells. Despite lacking activity in
yeast-killing assays, mutant Bax F, in which 8 of 10 charged residues
in
5-
6 were neutralized, displayed a gain-of-function phenotype
in mammalian cells. Inasmuch as the Bax-F mutant would be expected to
lack intrinsic pore-forming activity, we presumed that the ability of
Bax-F to kill mammalian cells but not yeast reflected the BH3-dependent
mechanism of killing by Bax. However, when the BH3 domain in Bax-F was
mutated (D68A) in a way previously shown to greatly reduce interactions
of the WT Bax protein with Bcl-2 and Bcl-XL
(51), the resulting Bax-(F+BH3) mutant protein still
retained substantial apoptotic activity. Our attempts to explore the
basis for retention of activity by the Bax-(F+BH3) protein have
revealed that it retains the ability to associate with
Bcl-XL in coimmunoprecipitation assays. Thus, whereas the BH3 mutation (D68A) greatly reduces binding to Bcl-XL
within the context of the otherwise WT Bax protein (51), it
does not prevent association with Bcl-XL within the context
of the Bax-F protein. Moreover, the Bax-F protein displayed enhanced
association with Bcl-XL compared to that of WT Bax,
suggesting that alanine substitution neutralization of charged residues
in the
5-
6 region of Bax facilitates its interaction with
antiapoptotic Bcl-2 family proteins.
The reasons for the apparently enhanced interaction of Bax-F with
Bcl-X
L remain to be elucidated. One possibility is that
the
superior membrane-inserting ability of Bax-F compared to WT
Bax allows
it to more fully expose the amphipathic face of its
BH3 domain, which
has been shown to be involved in dimerizing
with antiapoptotic Bcl-2
family proteins. Accordingly, perhaps
the D68A mutation within the BH3
domain is no longer an impediment
to BH3-mediated dimerization in this
setting. Alternatively, recent
chemical cross-linking studies and other
investigations have suggested
that membrane-inserted Bax and Bcl-2 or
Bcl-X
L may physically
interact in membranes in a
BH3-independent fashion (
44). By
favoring membrane
insertion, therefore, it is possible that the
neutralizing alanine
substitution mutations in the

5-

6 region
of the Bax-F protein
enhance this BH3-independent association
of Bax with antiapoptotic
proteins, such as Bcl-X
L, affording
the protein a
gain-of-function phenotype. This putative enhanced
interaction of the
membrane-inserted forms of Bax and Bcl-X
L hypothetically
could abrogate or modify the intrinsic channel activity of the
Bcl-X
L protein (
44) or could improve the ability
of Bax to compete
with Bcl-X
L for interactions with other
proteins in mitochondrial
membranes, such as VDAC or ANT (
22,
29,
42). Further investigations
are required to distinguish among
these possible explanations
for the data presented here and to further
delineate the mechanisms
of the Bax protein
function.
Conclusions.
The results reported here support prior
suggestions that the Bax protein has a dual mechanism of action: (i)
formation of pores in cellular membranes, attributed to the putative
pore-forming
5-
6 region, and (ii) heterodimerization with
antiapoptotic Bcl-2 family members through the BH3 domain of Bax. Our
results, however, also suggest that the
5-
6 domain participates
in or regulates interactions of Bax with antiapoptotic Bcl-2 family
proteins, such as Bcl-XL, and that it influences
mitochondrial targeting. It remains to be determined whether the
5-
6 domain of Bax participates directly in interaction of the
membrane-inserted Bax protein with other integral membrane proteins,
such as components of the mitochondrial permeability transition pore complex.
 |
ACKNOWLEDGMENTS |
We thank the University of California Tobacco Related Disease
Research Program (grant 7FT-0100) and NIH (GM60554) for generous support.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Burnham
Institute, 10901 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (858) 646-3140. Fax: (858) 646-3194. E-mail: jreed{at}burnham-inst.org.
Present address: Institut Pasteur, URA 1773 CNRS, 75724 Paris Cedex
15, France.
 |
REFERENCES |
| 1.
|
Antonsson, B.,
F. Conti,
A. Ciavatta,
S. Montessuit,
S. Lewis,
I. Martinou,
L. Bernasconi,
A. Bernard,
J.-J. Mermod,
G. Mazzei,
K. Maundrell,
F. Gambale,
R. Sadoul, and J.-C. Martinou.
1997.
Inhibition of Bax channel-forming activity by Bcl-2.
Science
277:370-372[Abstract/Free Full Text].
|
| 2.
|
Chou, J.,
H. Li,
G. Salvesen,
J. Yuan, and G. Wagner.
1999.
Solution structure of BID, an intracellular amplifier of apoptotic signaling.
Cell
96:615-624[CrossRef][Medline].
|
| 3.
|
Cramer, W. A.,
J. B. Heymann,
S. L. Schendel,
B. N. Deriy,
F. S. Cohen,
P. A. Elkins, and C. V. Stauffacher.
1995.
Structure-function of the channel-forming colicins.
Annu. Rev. Biophys. Biomol. Struct.
24:611-641[CrossRef][Medline].
|
| 4.
|
Deckwerth, T. L.,
J. L. Elliott,
C. M. Knudson,
E. M. Johnson, Jr.,
W. D. Snider, and S. J. Korsmeyer.
1996.
BAX is required for neuronal death after trophic factor deprivation and during development.
Neuron
17:401-411[CrossRef][Medline].
|
| 5.
|
Desagher, S.,
A. Osen-Sand,
A. Nichols,
R. Eskes,
S. Montessuit,
S. Lauper,
K. Maundrell,
B. Antonsson, and J.-C. Martinou.
1998.
Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c depletion during apoptosis.
J. Cell Biol.
144:891-901[Abstract/Free Full Text].
|
| 6.
|
Goping, I.,
A. Gross,
J. Lavoie,
M. Nguyen,
R. Jemmerson,
K. Roth,
S. Korsmeyer, and G. Shore.
1998.
Regulated targeting of BAX mitochondria.
J. Cell Biol.
143:207-215[Abstract/Free Full Text].
|
| 7.
|
Green, D., and J. Reed.
1998.
Mitochondria and apoptosis.
Science
281:1309-1312[Abstract/Free Full Text].
|
| 8.
|
Gross, A.,
J. Jockel,
M. Wei, and S. Korsmeyer.
1998.
Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis.
EMBO J.
17:3878-3885[CrossRef][Medline].
|
| 9.
|
Han, J.,
P. Sabbatini,
D. Perez,
L. Rao,
D. Modha, and E. White.
1996.
The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein.
Genes Dev.
10:461-477[Abstract/Free Full Text].
|
| 10.
|
Ho, S.,
H. Hunt,
R. Horton,
J. Pullen, and L. Pease.
1989.
Site-directed mutagenesis by overlap extension using the polymerase chain reaction.
Gene
77:51-59[CrossRef][Medline].
|
| 11.
|
Hsu, Y.-T.,
K. G. Wolter, and R. J. Youle.
1997.
Cytosol-to-membrane redistribution of Bax and Bcl-XL during apoptosis.
Proc. Natl. Acad. Sci. USA
94:3668-3672[Abstract/Free Full Text].
|
| 12.
|
Hsu, Y. T., and R. J. Youle.
1997.
Nonionic detergents induce dimerization among members of the Bcl-2 family.
J. Biol. Chem.
272:13829-13834[Abstract/Free Full Text].
|
| 13.
|
Jurgensmeier, J.,
S. Krajewski,
R. Armstrong,
G. Wilson,
T. Oltersdorf,
L. Fritz,
J. Reed, and S. Ottilie.
1997.
Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe.
Mol. Biol. Cell
8:325-339[Abstract].
|
| 14.
|
Jurgensmeier, J. M.,
Z. Xie,
Q. Deveraux,
L. Ellerby,
D. Bredesen, and J. C. Reed.
1998.
Bax directly induces release of cytochrome c from isolated mitochondria.
Proc. Natl. Acad. Sci. USA
5:4997-5002.
|
| 15.
|
Knudson, C. M.,
K. S. K. Tung,
W. G. Tourtellotte,
G. A. J. Brown, and S. J. Korsmeyer.
1995.
Bax-deficient mice with lymphoid hyperplasia and male germ cell death.
Science
270:96-99[Abstract/Free Full Text].
|
| 16.
|
Krajewski, S.,
M. Krajewska,
A. Shabaik,
T. Miyashita,
H.-G. Wang, and J. C. Reed.
1994.
Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.
Am. J. Pathol.
145:1323-1333[Abstract].
|
| 17.
|
Krajewski, S.,
M. Krajewska,
A. Shabaik,
H.-G. Wang,
S. Irie,
L. Fong, and J. C. Reed.
1994.
Immunohistochemical analysis of in vivo patterns of Bcl-X expression.
Cancer Res.
54:5501-5507[Abstract/Free Full Text].
|
| 18.
|
Krishtalik, L. I., and W. A. Cramer.
1995.
On the physical basis for the cis-positive rule describing protein orientation in biological membranes.
FEBS Lett.
369:140-143[CrossRef][Medline].
|
| 19.
|
Lewis, S.,
S. Bethell,
S. Patel,
J.-C. Martinou, and B. Antonsson.
1998.
Purification and biochemical properties of soluble recombinant human Bax.
Protein Expr. Purif.
13:120-126[CrossRef][Medline].
|
| 20.
|
Li, H.,
H. Zhu,
C. Xu, and J. Yuan.
1998.
Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.
Cell
94:491-501[CrossRef][Medline].
|
| 21.
|
Manon, S.,
B. Chaudhuri, and M. Buérin.
1997.
Release of cytochrome c and decrease of cytochrome c oxidase in Bax-expressing yeast cells, and prevention of these effects by coexpression of Bcl-XL.
FEBS Lett.
415:29-32[CrossRef][Medline].
|
| 22.
|
Marzo, I.,
C. Brenner,
N. Zamzami,
J. M. Jurgensmeier,
S. A. Susin,
H. L. A. Vieira,
M.-C. Prevost,
Z. Xie,
S. Matsuyama,
J. C. Reed, and G. Kroemer.
1998.
Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis.
Science
281:2027-2031[Abstract/Free Full Text].
|
| 23.
|
Matsuyama, S.,
S. Schendel,
Z. Xie, and J. Reed.
1998.
Cytoprotection by Bcl-2 requires the pore-forming 5 and 6 helices.
J. Biol. Chem.
273:30995-31001[Abstract/Free Full Text].
|
| 24.
|
Matsuyama, S.,
Q. Xu,
J. Velours, and J. C. Reed.
1998.
The mitochondrial F0F1-ATPase proton pump is required for function of proapoptotic protein Bax in yeast and mammalian cells.
Mol. Cell
1:327-336[CrossRef][Medline].
|
| 25.
|
McDonnell, J.,
D. Fushman,
C. Milliman,
S. Korsmeyer, and D. Cowburn.
1999.
Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists.
Cell
96:625-634[CrossRef][Medline].
|
| 26.
|
Minn, A. J.,
P. Velez,
S. L. Schendel,
H. Liang,
S. W. Muchmore,
S. W. Fesik,
M. Fill, and C. B. Thompson.
1997.
Bcl-xL forms an ion channel in synthetic lipid membranes.
Nature
385:353-357[CrossRef][Medline].
|
| 27.
|
Miyashita, T.,
S. Krajewski,
M. Krajewska,
H. G. Wang,
H. K. Lin,
B. Hoffman,
D. Lieberman, and J. C. Reed.
1994.
Tumor suppressor p53 is a regulator of BCL-2 and BAX in gene expression in vitro and in vivo.
Oncogene
9:1799-1805[Medline].
|
| 28.
|
Montal, M.
1996.
Protein folds in channel structure.
Curr. Opin. Struct. Biol.
6:499-510[CrossRef][Medline].
|
| 29.
|
Narita, M.,
S. Shimizu,
T. Ito,
T. Chittenden,
R. J. Lutz,
H. Matsuda, and Y. Tsujimoto.
1998.
Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria.
Proc. Natl. Acad. Sci. USA
95:14681-14686[Abstract/Free Full Text].
|
| 30.
|
Nechushtan, A.,
C. Smith,
Y.-T. Hsu, and R. Youle.
1999.
Conformation of the Bax C-terminus regulates subcellular location and cell death.
EMBO J.
18:2330-2341[CrossRef][Medline].
|
| 31.
|
Oltvai, Z.,
C. Milliman, and S. Korsmeyer.
1993.
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
Cell
74:609-619[CrossRef][Medline].
|
| 32.
|
Pastorino, J. G.,
S. T. Chen,
M. Tafani,
J. W. Snyder, and J. L. Farber.
1998.
The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition.
J. Biol. Chem.
273:7770-7775[Abstract/Free Full Text].
|
| 33.
|
Reed, J.
1998.
Bcl-2 family proteins.
Oncogene
17:3225-3236[CrossRef][Medline].
|
| 34.
|
Sato, T.,
M. Hanada,
S. Bodrug,
S. Irie,
N. Iwama,
L. H. Boise,
C. B. Thompson,
E. Golemis,
L. Fong,
H.-G. Wang, and J. C. Reed.
1994.
Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system.
Proc. Natl. Acad. Sci. USA
91:9238-9242[Abstract/Free Full Text].
|
| 35.
|
Sattler, M.,
H. Liang,
D. Nettesheim,
R. P. Meadows,
J. E. Harlan,
M. Eberstadt,
H. S. Yoon,
S. B. Shuker,
B. S. Chang,
A. J. Minn,
C. B. Thompson, and S. W. Fesik.
1997.
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Science
275:983-986[Abstract/Free Full Text].
|
| 36.
|
Schendel, S.,
M. Montal, and J. C. Reed.
1998.
Bcl-2 family proteins as ion-channels.
Cell Death Differ.
5:372-380[CrossRef][Medline].
|
| 37.
|
Schendel, S. L.,
R. Azimov,
K. Powlowski,
A. Godzik,
B. L. Kagan, and J. C. Reed.
1999.
Ion channel activity of the BH3 only Bcl-2 family member, BID.
J. Biol. Chem.
274:21932-21936[Abstract/Free Full Text].
|
| 38.
|
Schendel, S. L.,
Z. Xie,
M. O. Montal,
S. Matsuyama,
M. Montal, and J. C. Reed.
1997.
Channel formation by antiapoptotic protein Bcl-2.
Proc. Natl. Acad. Sci. USA
94:5113-5118[Abstract/Free Full Text].
|
| 39.
|
Schlesinger, P.,
A. Gross,
X.-M. Yin,
K. Yamamoto,
M. Saito,
G. Waksman, and S. Korsmeyer.
1997.
Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2.
Proc. Natl. Acad. Sci. USA
94:11357-11362[Abstract/Free Full Text].
|
| 40.
|
Shimizu, Y.,
M. Narita, and Y. Tsujimoto.
1999.
Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC.
Nature
399:483-487[CrossRef][Medline].
|
| 41.
|
Silverman, J. A.,
J. A. Mindell,
A. Finkelstein,
W. H. Shen, and R. J. Collier.
1994.
Mutational analysis of the helical hairpin region of diphtheria toxin transmembrane domain.
J. Biol. Chem.
269:22524-22532[Abstract/Free Full Text].
|
| 42.
|
Vander Heiden, M.,
N. Chandel,
P. Schumacker, and C. Thompson.
1999.
Bcl-XL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange.
Mol. Cell
3:159-167[CrossRef][Medline].
|
| 43.
|
Wang, H. G.,
U. R. Rapp, and J. C. Reed.
1996.
Bcl-2 targets the protein kinase Raf-1 to mitochondria.
Cell
87:629-638[CrossRef][Medline].
|
| 44.
|
Wang, K.,
A. Gross,
G. Waksman, and S. J. Korsmeyer.
1998.
Mutagenesis of the BH3 domain of Bax identifies critical residues for dimerization and killing.
Mol. Cell. Biol.
18:6083-6089[Abstract/Free Full Text].
|
| 45.
|
Wang, K.,
W.-M. Yin,
D. T. Chao,
C. L. Milliman, and S. J. Korsmeyer.
1996.
BID: a novel BH3 domain-only death agonist.
Genes Dev.
10:2859-2869[Abstract/Free Full Text].
|
| 46.
|
Wolter, K. G.,
Y. T. Hsu,
C. L. Smith,
A. Nechushtan,
X. G. Xi, and R. J. Youle.
1997.
Movement of Bax from the cytosol to mitochondria during apoptosis.
J. Cell Biol.
139:1281-1292[Abstract/Free Full Text].
|
| 47.
|
Xiang, J.,
D. T. Chao, and S. J. Korsmeyer.
1996.
BAX-induced cell death may not require interleukin 1 -converting enzyme-like proteases.
Proc. Natl. Acad. Sci. USA
93:14559-14563[Abstract/Free Full Text].
|
| 48.
|
Yin, X. M.,
Z. N. Oltvai, and S. J. Korsmeyer.
1994.
BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.
Nature
369:321-323[CrossRef][Medline].
|
| 49.
|
Zha, H.,
C. Aime-Sempe,
T. Sato, and J. C. Reed.
1996.
Pro-apoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2.
J. Biol. Chem.
271:7440-7444[Abstract/Free Full Text].
|
| 50.
|
Zha, H.,
H. Fisk,
M. Yaffe,
N. Mahajan,
B. Herman, and J. Reed.
1996.
Structure-function comparisons of proapoptotic protein Bax in yeast and mammalian cells.
Mol. Cell. Biol.
16:6494-6508[Abstract].
|
| 51.
|
Zha, H., and J. C. Reed.
1997.
Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells.
J. Biol. Chem.
272:31482-31488[Abstract/Free Full Text].
|
Molecular and Cellular Biology, March 2000, p. 1604-1615, Vol. 20, No. 5
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ming, L., Wang, P., Bank, A., Yu, J., Zhang, L.
(2006). PUMA Dissociates Bax and Bcl-XL to Induce Apoptosis in Colon Cancer Cells. J. Biol. Chem.
281: 16034-16042
[Abstract]
[Full Text]
-
Weng, J-R, Chen, C-Y, Pinzone, J J, Ringel, M D, Chen, C-S
(2006). Beyond peroxisome proliferator-activated receptor {gamma} signaling: the multi-facets of the antitumor effect of thiazolidinediones.. Endocr Relat Cancer
13: 401-413
[Abstract]
[Full Text]
-
Zhu, Y., Liu, X., Hildeman, D., Peyerl, F. W., White, J., Kushnir, E., Kappler, J., Marrack, P.
(2006). Bax does not have to adopt its final form to drive T cell death. JEM
203: 1147-1152
[Abstract]
[Full Text]
-
Zhang, D., Mott, J. L., Chang, S.-W., Stevens, M., Mikolajczak, P., Zassenhaus, H. P.
(2005). Mitochondrial DNA mutations activate programmed cell survival in the mouse heart. Am. J. Physiol. Heart Circ. Physiol.
288: H2476-H2483
[Abstract]
[Full Text]
-
Cartron, P.-F., Arokium, H., Oliver, L., Meflah, K., Manon, S., Vallette, F. M.
(2005). Distinct Domains Control the Addressing and the Insertion of Bax into Mitochondria. J. Biol. Chem.
280: 10587-10598
[Abstract]
[Full Text]
-
Shiau, C.-W., Yang, C.-C., Kulp, S. K., Chen, K.-F., Chen, C.-S., Huang, J.-W., Chen, C.-S.
(2005). Thiazolidenediones Mediate Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Functions Independently of PPAR{gamma}. Cancer Res.
65: 1561-1569
[Abstract]
[Full Text]
-
Mc Gee, M. M., Greene, L. M., Ledwidge, S., Campiani, G., Nacci, V., Lawler, M., Williams, D. C., Zisterer, D. M.
(2004). Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL. J. Pharmacol. Exp. Ther.
310: 1084-1095
[Abstract]
[Full Text]
-
Sulistijo, E. S., Jaszewski, T. M., MacKenzie, K. R.
(2003). Sequence-specific Dimerization of the Transmembrane Domain of the "BH3-only" Protein BNIP3 in Membranes and Detergent. J. Biol. Chem.
278: 51950-51956
[Abstract]
[Full Text]
-
Cartron, P.-F., Priault, M., Oliver, L., Meflah, K., Manon, S., Vallette, F. M.
(2003). The N-terminal End of Bax Contains a Mitochondrial-targeting Signal. J. Biol. Chem.
278: 11633-11641
[Abstract]
[Full Text]
-
Kirchhoff, S.R., Gupta, S., Knowlton, A.A.
(2002). Cytosolic Heat Shock Protein 60, Apoptosis, and Myocardial Injury. Circulation
105: 2899-2904
[Abstract]
[Full Text]
-
Asoh, S., Ohtsu, T., Ohta, S.
(2000). The Super Anti-apoptotic Factor Bcl-xFNK Constructed by Disturbing Intramolecular Polar Interactions in Rat Bcl-xL. J. Biol. Chem.
275: 37240-37245
[Abstract]
[Full Text]